Brought to you by 
Bayer gets worldwide rights to Orion’s prostate cancer treatment ODM201
07 Aug 2019
Executive Summary
Drug, device, and point-of-care diagnostics company Orion Corp. licensed Bayer HealthCare LLC worldwide rights to its Phase II oral androgen receptor inhibitor ODM201 (now known as darolutamide) for prostate cancer.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer gets worldwide rights to Orion’s prostate cancer treatment ODM201
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice